Dr. César Trigueros Fernández
Hematopoiesis is a multi-stage developmental process that is maintained throughout life by a limited number of hematopoietic stem cells (HSC), which proliferate, self-renew, and differentiate into mature blood cells of all lineages. The classical hierarchy diagram where progenitors arise in an orderly fashion from HSC provides an overly simplified view. HSC could be described more accurately as groups of cells with varying developmental potentials based on intrinsic networks driven by transcription factors and inputs from the cellular niches in which they reside. Despite considerable progress to date, central questions about how to expand and maintain human HSC ex vivo for effective clinical transplantation remain to be answered.
The goal of the hematologic diseases program is to define new strategies for the expansion and differentiation of human HSC derived from cord blood for the treatment of leukemia and other hematopoietic disorders.
- Hematopoietic stem cell expansion
Initial efforts to expand HSC progenitors ex vivo have resulted in expansion of mature rather than immature HSC. Thus, our main objective proposes an improvement in the development of HSC expansion systems from umbilical cord blood. Additionally, we are interested in detail the relationship between HSC and Mesenchymal Stem Sell as one major component of the hematopoietic niche.
- Development of immunoregulation methods using mesenchymal stem cells
The studies carried out in recent years have allowed us to develop a genetic modification that increases immunoregulatory capacity of MSCs.
- Blizar Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, UK: Dr Dan Pennington.
- Centro Nacional de Investigaciones Cardiovasculares, Regenerative Cardiology Department, Madrid: Dr Antonio Bernad.
- CIEMAT, Madrid: Dr José Carlos Segovia.
- Instituto de Biomedicina y Biotecnología de Cantabria, Santander: Dr Ramón Merino.
- Fundación la Fe, Valencia: Dr Pilar Sepúlveda.